Developer docs
API playgroundTry for free, no card

Search company profiles

Qnova Lifesciences

Full company profile

uuid00sczzf

Namestring
Qnova Lifesciences
Legal namestring
LifeSciences Regulatory Solutions, LLC
Websiteurl
qnovals.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

QNova LifeSciences (legal entity LifeSciences Regulatory Solutions, LLC) is a private, founder-led global regulatory consulting and contract research organization (CRO) headquartered at the Maryland Innovation Center in Columbia, MD, with a second office in San Francisco. Founded in 2014 and rebranded from CSSi LifeSciences to QNova LifeSciences in January 2025, the firm specializes in guiding therapeutic and medical device developers through FDA approval pathways, with a documented track record of 85+ NDA/ANDA/CVM/BLA submissions, 200+ medical device approvals, and experience across 500+ drugs/biologics spanning 150+ indications and 30+ therapeutic areas.

The company's core offering is organized around four service lines: Regulatory Solutions (drug and medical device pathway strategy, medical writing, quality management systems including QMSR compliance), Clinical Services (Phase I through commercialization, with connections to 700+ clinical sites), Commercialization Solutions (US market entry and investor readiness), and Strategy & Project Management. Adjacent programs include the QNova Accelerator ($6,000, 12-month fee-based program with no equity taken) and QNova Capital (investment and funding support). The firm owns and operates the annual Partnering Forum held during J.P. Morgan Healthcare Week in San Francisco, which in 2026 attracted 1,400+ in-person participants from 600+ companies across 25 countries.

QNova generates revenue primarily through fee-for-service regulatory consulting engagements, the QNova Accelerator program fees, and tiered sponsorships for its annual Partnering Forum. Pricing for consulting is quote-based and not publicly disclosed. Its customer base spans early-stage life science startups, foreign companies entering the US market (notably Korea, Japan, and Europe), university and federal laboratory spinouts, and physician-entrepreneurs. Strategic alliances include Medical Technology Enterprise Consortium (MTEC), Liberi Group (exclusive consultancy), Phase Advance (AI-driven non-animal drug development), Biotoxtech (Korean non-clinical CRO), Tonic Bioventures (venture fund), Trifermed, and Jaunt.

Short descriptiontext

QNova LifeSciences is a private, founder-led FDA regulatory consulting CRO that guides drug and medical device developers through approval, clinical, and commercialization pathways. It serves early-stage startups, foreign companies entering the US, and academic spinouts, anchored by its annual JPM Healthcare Week Partnering Forum.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersColumbia, United States
HQ citystring
Columbia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regulatory consulting services, FDA approval strategy, clinical trial management, medical device consulting, life sciences CRO
Industry4 codes
PRIMARYHLAGAKAD
Quality Management Systems (QMS) & GxP Documentation
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Other Scientific and Technical Consulting Services54169
  • Other Scientific and Technical Consulting Services541690
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Regulatory Consulting
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Regulatory Consulting Services
TypeProfessional Services
Description

Fee-for-service regulatory consulting engagements providing strategic guidance on FDA approval pathways for drugs and medical devices, including submission services, quality management systems, and clinical development support

qnovals.com
2QNova Accelerator Program
TypeProfessional Services
Description

12-month fee-based accelerator program at $6,000 providing regulatory, commercialization, and investor-readiness support to early-stage life science companies

qnovals.com
3Partnering Forum Sponsorships
TypeProfessional Services
Description

Sponsorship packages for annual Partnering Forum during J.P. Morgan Healthcare Week, with tiered benefits including virtual platform access, logo placement, and speaking opportunities

qnovals.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
Pricing details2 tiers
1QNova Accelerator 12-Month Program
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

$6,000 for 12-month participation fee with no equity requirement and no application fee

qnovals.com
2Partnering Forum Sponsorship Packages
ModelOtherBilling cadenceAnnual
Notes

Tiered sponsorship levels including Platinum, Gold, Silver, and Bronze with varying benefits; on-site and virtual benefit packages available

qnovals.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Qnova Lifesciences provides regulatory consulting, clinical trial management, and commercialization services for medical device and therapeutic companies seeking FDA approval and U.S. market entry. The firm supports early-stage and international life sciences companies with strategy, clinical services, and non-dilutive funding guidance to bring products from concept to market.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 85+ FDA NDA, ANDA, CVM and BLA submissions
+4 more records
Product overview1 text field

QNova Lifesciences is a global Contract Research Organization (CRO) and consulting group offering an integrated portfolio of regulatory, clinical, and commercialization services for drugs and medical devices. The core offering consists of Regulatory Solutions (covering drug development, medical devices, medical writing, and quality management systems), Clinical Services (Phase I through commercialization), Commercialization Solutions (U.S. market entry and investor readiness), and Strategy & Project Management. The company also offers complementary programs including the QNova Accelerator (12-month fee-based support without equity), QNova Capital, and the Annual Partnering Forum during J.P. Morgan Healthcare Week. The integrated model combines regulatory expertise with commercialization guidance to help life science companies navigate FDA approval and market entry.

Product and service6 records
1Regulatory Solutions
CategoryRegulatory Consulting
2Clinical Services
CategoryClinical Research
3Commercialization Solutions
CategoryCommercialization Services
4Strategy and Project Management
CategoryStrategy Consulting
5QNova Accelerator
CategoryAccelerator Program
6Annual Partnering Forum
CategoryIndustry Event
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-12
Description

MTEC is a 501(c)(3) biomedical technology consortium collaborating with US government agencies under a 10-year renewable Other Transaction Agreement with the U.S. Army Medical Research and Development Command. MTEC co-hosts the annual QNova LifeSciences Partnering Forum during JPM Healthcare Week, focusing on medical solutions development for military personnel and civilians.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-12
Description

Liberi Group is a platinum sponsor and strategic partner providing strategic consultancy services. De Jong of Liberi Group led sessions at QNova's Partnering Forum on biotech partnership pitfalls.

3Phase Advance
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-10-16
Description

Phase Advance partnered with QNova Capital to forge an alliance ushering in AI-driven, non-animal drug development era, combining AI capabilities with regulatory expertise.

qnovals.com
Strategic tierMajorTypeGTM or Marketing PartnerAnnounced on2025-10-01
Description

Bessel is a platinum sponsor and co-host of the Build for Impact Startup Showcase during J.P. Morgan Healthcare Week, held at the QNova Partnering Forum.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-08-26
Description

OrganTech Inc. partnered with QNova LifeSciences for FDA application of next-generation bio-implant technology, leveraging QNova's regulatory expertise.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-05-13
Description

QNova LifeSciences and Liberi Group entered an exclusive consultancy agreement to provide joint services to clients requiring strategic partnership and business development guidance.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-11-26
Description

Partnership to accelerate global healthcare innovation access into the US market, combining Trifermed's international network with QNova's US regulatory expertise.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-04-18
Description

Partnership with market strategy leader Jaunt to provide market entry and strategy services to medtech innovators entering the US healthcare market.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-04-19
Description

Biotoxtech is Korea's No. 1 non-clinical CRO with GLP qualification from US FDA, conducting 2,000+ non-clinical studies annually. Partnership provides non-clinical trial and consulting services to facilitate FDA approval for Korean and foreign biotech companies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-06
Description

Tonic bioventures partnered with CSSi LifeSciences (now QNova) to form a new life science venture fund that will invest in breakthrough medical technologies, leveraging regulatory and early clinical expertise through QNova for portfolio companies. Fund plans to source 12-16 investments over 3-5 years.

11ITOCHU International
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Senior Manager Shohei Shibata discussed Japanese long-term strategic capital alignment with US life sciences innovation at QNova's Partnering Forum.

qnovals.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Eric Matson of Excellere Partners spoke at QNova's Partnering Forum on life sciences fundraising insights and market volatility.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Stifel released its 2026 biopharma market outlook presented at QNova Life Sciences, highlighting a shift toward disciplined early-stage investing.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large global CRO with full-service clinical, regulatory, and commercialization offerings. Overlaps with QNova on FDA regulatory strategy and clinical trial services, but operates at materially larger scale across pharma and biopharma.

TypeBroad incumbent
Description

Mid-to-large global CRO focused on clinical development for emerging biopharma. Comparable to QNova in serving small and mid-sized sponsors, but with much larger clinical operations and global delivery model.

TypeDirect peer
Description

Regulatory affairs, quality, and pharmacovigilance consulting CRO. Directly comparable service mix to QNova across regulatory submissions, GxP compliance, and clinical development for both pharma and medical device sponsors.

TypeBroad incumbent
Description

Largest global CRO and life sciences services platform with deep regulatory, clinical, and real-world evidence capabilities. Overlaps with QNova across FDA strategy and submissions, but at far greater scale and with proprietary technology platforms.

5Camargo Pharmaceutical Services
TypeDirect peer
Description

Specialized regulatory strategy and drug development consulting firm. Comparable in its focus on 505(b)(2), ANDA, and NDA pathway planning plus clinical and CMC support for small and mid-sized life sciences companies.

TypeBroad incumbent
Description

Major global CRO providing clinical, regulatory, and laboratory services. Comparable on regulatory affairs and clinical development services, but serves enterprise pharma with much broader operational footprint than QNova.

TypeDirect peer
Description

Mid-size CRO focused on emerging biopharma and medical device sponsors with adaptive clinical and regulatory services. Highly comparable to QNova in serving small and mid-sized life sciences companies seeking integrated regulatory and clinical support.

TypeDirect peer
Description

Global regulatory, compliance, and quality consulting firm serving pharma, biotech, and medical device companies. Highly comparable to QNova as a fee-for-service regulatory consultancy covering FDA submissions, QMS, and clinical compliance across therapeutic and device portfolios.

TypeBroad incumbent
Description

Major CRO spanning preclinical, clinical, and manufacturing services. Comparable to QNova's clinical services and FDA strategy offerings, though with much broader preclinical and CDMO capabilities.

TypeBroad incumbent
Description

Mid-size global CRO providing clinical and post-approval services. Overlaps with QNova on clinical trial execution and regulatory strategy, particularly for mid-sized pharma and biotech sponsors.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Qnova Lifesciences

Pharmaceutical Regulatory Consultingqnovals.com

QNova LifeSciences is a private, founder-led FDA regulatory consulting CRO that guides drug and medical device developers through approval, clinical, and commercialization pathways. It serves early-stage startups, foreign companies entering the US, and academic spinouts, anchored by its annual JPM Healthcare Week Partnering Forum.

What Qnova Lifesciences does

QNova LifeSciences (legal entity LifeSciences Regulatory Solutions, LLC) is a private, founder-led global regulatory consulting and contract research organization (CRO) headquartered at the Maryland Innovation Center in Columbia, MD, with a second office in San Francisco. Founded in 2014 and rebranded from CSSi LifeSciences to QNova LifeSciences in January 2025, the firm specializes in guiding therapeutic and medical device developers through FDA approval pathways, with a documented track record of 85+ NDA/ANDA/CVM/BLA submissions, 200+ medical device approvals, and experience across 500+ drugs/biologics spanning 150+ indications and 30+ therapeutic areas.

The company's core offering is organized around four service lines: Regulatory Solutions (drug and medical device pathway strategy, medical writing, quality management systems including QMSR compliance), Clinical Services (Phase I through commercialization, with connections to 700+ clinical sites), Commercialization Solutions (US market entry and investor readiness), and Strategy & Project Management. Adjacent programs include the QNova Accelerator ($6,000, 12-month fee-based program with no equity taken) and QNova Capital (investment and funding support). The firm owns and operates the annual Partnering Forum held during J.P. Morgan Healthcare Week in San Francisco, which in 2026 attracted 1,400+ in-person participants from 600+ companies across 25 countries.

QNova generates revenue primarily through fee-for-service regulatory consulting engagements, the QNova Accelerator program fees, and tiered sponsorships for its annual Partnering Forum. Pricing for consulting is quote-based and not publicly disclosed. Its customer base spans early-stage life science startups, foreign companies entering the US market (notably Korea, Japan, and Europe), university and federal laboratory spinouts, and physician-entrepreneurs. Strategic alliances include Medical Technology Enterprise Consortium (MTEC), Liberi Group (exclusive consultancy), Phase Advance (AI-driven non-animal drug development), Biotoxtech (Korean non-clinical CRO), Tonic Bioventures (venture fund), Trifermed, and Jaunt.

Qnova Lifesciences firmographics

Firmographics
Name
Qnova Lifesciences
Legal name
LifeSciences Regulatory Solutions, LLC
Website
https://qnovals.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
QNova LifeSciences is a private, founder-led FDA regulatory consulting CRO that guides drug and medical device developers through approval, clinical, and commercialization pathways. It serves early-stage startups, foreign companies entering the US, and academic spinouts, anchored by its annual JPM Healthcare Week Partnering Forum.
Ownership category
akta.pro rank

Qnova Lifesciences industry classification

Industry
Product category
Pharmaceutical Regulatory Consulting
NAICS
Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169), Other Scientific and Technical Consulting Services (541690)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAKAD
Quality Management Systems (QMS) & GxP Documentation
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination

Keywords

  • Regulatory consulting services
  • FDA approval strategy
  • Clinical trial management
  • Medical device consulting
  • Life sciences CRO

Where Qnova Lifesciences is headquartered

Location

Headquarters

HQ city
Columbia
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Qnova Lifesciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Regulatory Consulting Services: Fee-for-service regulatory consulting engagements providing strategic guidance on FDA approval pathways for drugs and medical devices, including submission services, quality management systems, and clinical development support
  2. QNova Accelerator Program: 12-month fee-based accelerator program at $6,000 providing regulatory, commercialization, and investor-readiness support to early-stage life science companies
  3. Partnering Forum Sponsorships: Sponsorship packages for annual Partnering Forum during J.P. Morgan Healthcare Week, with tiered benefits including virtual platform access, logo placement, and speaking opportunities

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractQNova Accelerator 12-Month Program
OtherAnnualPartnering Forum Sponsorship Packages

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Qnova Lifesciences product offering

Product offering

Core offering

Qnova Lifesciences provides regulatory consulting, clinical trial management, and commercialization services for medical device and therapeutic companies seeking FDA approval and U.S. market entry. The firm supports early-stage and international life sciences companies with strategy, clinical services, and non-dilutive funding guidance to bring products from concept to market.

Product overview

QNova Lifesciences is a global Contract Research Organization (CRO) and consulting group offering an integrated portfolio of regulatory, clinical, and commercialization services for drugs and medical devices. The core offering consists of Regulatory Solutions (covering drug development, medical devices, medical writing, and quality management systems), Clinical Services (Phase I through commercialization), Commercialization Solutions (U.S. market entry and investor readiness), and Strategy & Project Management. The company also offers complementary programs including the QNova Accelerator (12-month fee-based support without equity), QNova Capital, and the Annual Partnering Forum during J.P. Morgan Healthcare Week. The integrated model combines regulatory expertise with commercialization guidance to help life science companies navigate FDA approval and market entry.

Differentiator

Problem solved

Functional benefit

Products and services

  • Regulatory Solutions
  • Clinical Services
  • Commercialization Solutions
  • Strategy and Project Management
  • QNova Accelerator
  • Annual Partnering Forum

Quantifiable outcome

  • 85+ FDA NDA, ANDA, CVM and BLA submissions
  • +4 more outcomes

Companies that use Qnova Lifesciences

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Qnova Lifesciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Qnova Lifesciences partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core, major and minor.

  • Medical Technology Enterprise Consortium (MTEC)coreStrategic or Co-development Partner · 12 January 2026MTEC is a 501(c)(3) biomedical technology consortium collaborating with US government agencies under a 10-year renewable Other Transaction Agreement with the U.S. Army Medical Research and Development Command. MTEC co-hosts the annual QNova LifeSciences Partnering Forum during JPM Healthcare Week, focusing on medical solutions development for military personnel and civilians.
  • Liberi GroupcoreStrategic or Co-development Partner · 12 January 2026Liberi Group is a platinum sponsor and strategic partner providing strategic consultancy services. De Jong of Liberi Group led sessions at QNova's Partnering Forum on biotech partnership pitfalls.
  • Phase AdvancemajorStrategic or Co-development Partner · 16 October 2025Phase Advance partnered with QNova Capital to forge an alliance ushering in AI-driven, non-animal drug development era, combining AI capabilities with regulatory expertise.
  • BesselmajorGTM or Marketing Partner · 1 October 2025Bessel is a platinum sponsor and co-host of the Build for Impact Startup Showcase during J.P. Morgan Healthcare Week, held at the QNova Partnering Forum.
  • OrganTech Inc.majorStrategic or Co-development Partner · 26 August 2025OrganTech Inc. partnered with QNova LifeSciences for FDA application of next-generation bio-implant technology, leveraging QNova's regulatory expertise.
  • Liberi GroupcoreImplementation/ SI/ Consulting Partner · 13 May 2025QNova LifeSciences and Liberi Group entered an exclusive consultancy agreement to provide joint services to clients requiring strategic partnership and business development guidance.
  • TrifermedmajorStrategic or Co-development Partner · 26 November 2024Partnership to accelerate global healthcare innovation access into the US market, combining Trifermed's international network with QNova's US regulatory expertise.
  • JauntminorStrategic or Co-development Partner · 18 April 2024Partnership with market strategy leader Jaunt to provide market entry and strategy services to medtech innovators entering the US healthcare market.
  • BiotoxtechmajorStrategic or Co-development Partner · 19 April 2023Biotoxtech is Korea's No. 1 non-clinical CRO with GLP qualification from US FDA, conducting 2,000+ non-clinical studies annually. Partnership provides non-clinical trial and consulting services to facilitate FDA approval for Korean and foreign biotech companies.
  • Tonic BioventurescoreStrategic or Co-development Partner · 6 January 2021Tonic bioventures partnered with CSSi LifeSciences (now QNova) to form a new life science venture fund that will invest in breakthrough medical technologies, leveraging regulatory and early clinical expertise through QNova for portfolio companies. Fund plans to source 12-16 investments over 3-5 years.
  • ITOCHU InternationalminorStrategic or Co-development PartnerSenior Manager Shohei Shibata discussed Japanese long-term strategic capital alignment with US life sciences innovation at QNova's Partnering Forum.
  • Excellere PartnersminorStrategic or Co-development PartnerEric Matson of Excellere Partners spoke at QNova's Partnering Forum on life sciences fundraising insights and market volatility.
  • StifelminorStrategic or Co-development PartnerStifel released its 2026 biopharma market outlook presented at QNova Life Sciences, highlighting a shift toward disciplined early-stage investing.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Qnova Lifesciences competitors and assessment

Company assessment

Broad incumbents

  • Parexel: Large global CRO with full-service clinical, regulatory, and commercialization offerings. Overlaps with QNova on FDA regulatory strategy and clinical trial services, but operates at materially larger scale across pharma and biopharma.
  • Medpace: Mid-to-large global CRO focused on clinical development for emerging biopharma. Comparable to QNova in serving small and mid-sized sponsors, but with much larger clinical operations and global delivery model.
  • IQVIA: Largest global CRO and life sciences services platform with deep regulatory, clinical, and real-world evidence capabilities. Overlaps with QNova across FDA strategy and submissions, but at far greater scale and with proprietary technology platforms.
  • ICON plc: Major global CRO providing clinical, regulatory, and laboratory services. Comparable on regulatory affairs and clinical development services, but serves enterprise pharma with much broader operational footprint than QNova.
  • Charles River Laboratories: Major CRO spanning preclinical, clinical, and manufacturing services. Comparable to QNova's clinical services and FDA strategy offerings, though with much broader preclinical and CDMO capabilities.
  • Worldwide Clinical Trials: Mid-size global CRO providing clinical and post-approval services. Overlaps with QNova on clinical trial execution and regulatory strategy, particularly for mid-sized pharma and biotech sponsors.

Direct peers

  • PharmaLex: Regulatory affairs, quality, and pharmacovigilance consulting CRO. Directly comparable service mix to QNova across regulatory submissions, GxP compliance, and clinical development for both pharma and medical device sponsors.
  • Camargo Pharmaceutical Services: Specialized regulatory strategy and drug development consulting firm. Comparable in its focus on 505(b)(2), ANDA, and NDA pathway planning plus clinical and CMC support for small and mid-sized life sciences companies.
  • Clinipace Worldwide: Mid-size CRO focused on emerging biopharma and medical device sponsors with adaptive clinical and regulatory services. Highly comparable to QNova in serving small and mid-sized life sciences companies seeking integrated regulatory and clinical support.
  • ProPharma Group: Global regulatory, compliance, and quality consulting firm serving pharma, biotech, and medical device companies. Highly comparable to QNova as a fee-for-service regulatory consultancy covering FDA submissions, QMS, and clinical compliance across therapeutic and device portfolios.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Qnova Lifesciences social profiles

Digital presence

Qnova Lifesciences compliance and trust

Trust signal

Compliance4 records

Qnova Lifesciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Qnova Lifesciences leadership team

Management profile

Number of profiles

Profiles2 records

Qnova Lifesciences subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Qnova Lifesciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Qnova Lifesciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qnova Lifesciences

What does Qnova Lifesciences do?

Qnova Lifesciences provides regulatory consulting, clinical trial management, and commercialization services for medical device and therapeutic companies seeking FDA approval and U.S. market entry. The firm supports early-stage and international life sciences companies with strategy, clinical services, and non-dilutive funding guidance to bring products from concept to market.

Is Qnova Lifesciences a public or private company?

Qnova Lifesciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Qnova Lifesciences founded?

Qnova Lifesciences was founded in 2014. It employs 11 to 50 people.

Where is Qnova Lifesciences based?

Qnova Lifesciences is headquartered in Columbia, United States, in the North America region.

How does Qnova Lifesciences make money?

Three revenue lines are on record. Regulatory Consulting Services are the primary driver. The others are QNova Accelerator Program and partnering Forum Sponsorships.

Who are Qnova Lifesciences's main competitors?

Broad incumbents on record are Parexel, Medpace, IQVIA, ICON plc, Charles River Laboratories and Worldwide Clinical Trials. Direct peers are PharmaLex, Camargo Pharmaceutical Services, Clinipace Worldwide and ProPharma Group.

Does Qnova Lifesciences have an API?

No public API is recorded for Qnova Lifesciences.

What industry is Qnova Lifesciences in?

Qnova Lifesciences's product category is Pharmaceutical Regulatory Consulting. Its primary akta.pro industry code is HLAGAKAD, Quality Management Systems (QMS) & GxP Documentation, with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrtimesOrganitech has completed fundraising for the next growth stage.Organ Tech completed fundraising for its next growth stage, accelerating research on Bio-hybrid Tooth and Third Cell hair follicle cells. The company will expand operations domestically and internationally, with a clinical study of periodontal membrane-connected implants starting February 1, 2025, and a consulting contract with QNova LifeSciences for FDA approval preparations.BiobuzzDecoding Non-Dilutive Funding: Insights for MedTech SuccessChris Steele, Chief Strategy and Business Development Officer at the Medical Technology Enterprise Consortium (MTEC), led a session at QNova LifeSciences' 12th Annual Partnering Forum addressing how medtech companies misunderstand non-dilutive funding, framing it as a translation challenge rather than a financial lifeline. Steele argued that success depends on navigating signal, sponsorship, and requirements within a complex federal ecosystem, noting that roughly 60 percent of certain DoD grant opportunities have been eliminated amid broader federal R&D disruptions. The session emphasized that companies must understand internal DoD structures, distinguish between research funding and procurement pathways, and recognize that non-dilutive funding requires discipline and alignment comparable to venture funding.BiobuzzBridging U.S. Innovation and Japanese Capital in Life SciencesAt QNova LifeSciences' 12th Annual Partnering Forum cohosted by MTEC, ITOCHU International's Senior Manager Shohei Shibata outlined how Japanese long-term strategic capital is increasingly aligning with U.S. life sciences innovation. The discussion highlighted that while U.S. companies bring innovation and execution speed, Japanese investors offer patience and balance-sheet strength—a combination particularly suited for complex, regulated healthcare platforms requiring long-term operational commitment. The model being described moves away from centralized global structures toward localized platforms connected by shared ownership and strategy, enabling cross-border expansion while respecting regulatory and cultural differences.BiobuzzUnlocking Non-Dilutive Funding: A Signal of ReadinessAt QNova LifeScience's 12th Annual Partnering Forum at JPM Healthcare Week co-hosted by MTEC, industry leaders discussed how non-dilutive federal funding has evolved beyond a capital source into a validation mechanism for biopharma and medtech companies' operational readiness. The discussion highlighted that companies able to secure and execute federal funding demonstrate greater translational clarity, operational maturity, and execution capability—qualities that correlate with long-term success. The session reframed non-dilutive funding as an early indicator of whether a company is built to operate under complex regulatory, clinical, and commercial constraints.BiobuzzAvoiding Common Pitfalls in Biotech Partnerships: Key InsightsAt QNova's 12th Annual Partnering Forum during JP Morgan Healthcare Week, Bram de Jong of the Liberi Group outlined five common mistakes biotech companies make in pharma partnerships, including starting outreach too late, underestimating IP strategy, neglecting commercial planning, mixing rare and broad indications, and overselling assets.BiobuzzNavigating Volatility: Life Sciences Fundraising InsightsDay One of the QNova Life Sciences Partnering Forum at JPM Healthcare Week heard from speakers including Eric Matson of Excellere Partners that life sciences fundraising is undergoing a structural reset marked by sustained volatility, heightened selectivity, and increased execution risk rather than a temporary slowdown. The forum highlighted key shifts including AI becoming a baseline investor expectation, commercial strategy being pushed earlier into company lifecycles, and a disconnect between abundant dry powder and constrained deployment due to lack of conviction. Speakers emphasized that founders must now demonstrate stronger capital discipline, clear value creation logic, and operational readiness to transfer conviction to investors in an environment where exits are longer and more operational.BiobuzzThe Case for a Multi-Year Biotech Upswing – Leading Analyst’s Read on the Market ahead of JPM WeekStifel released a 2026 biopharma market outlook arguing that the biotech sector is entering a multi-year expansion driven by scale in obesity therapeutics and improved R&D productivity. This analysis, presented at the JPM Healthcare Week via QNova Life Sciences, highlights a shift toward disciplined, early-stage investing as capital flows selectively to high-conviction opportunities.PR NewswireAn Upcoming Funding Opportunity and Two National Events: MTEC Prepares for a Big Start to 2026The Medical Technology Enterprise Consortium (MTEC) announced three initiatives for early 2026: the 12th Annual Partnering Forum co-hosted with QNova LifeSciences during JPM Healthcare Week, a Defense Health Agency Request for Project Proposals for domestic blood collection and storage bag manufacturing, and a Platelet & Platelet-like Products State of Technology Meeting. The Defense Health Agency has up to $4 million available for this effort, with anticipated Phase I awards of approximately $1 million to $3 million, requiring MTEC membership for proposal submission. MTEC is collaborating with the Biomedical Advanced Research and Development Authority and Defense Health Agency on the February 2026 State of Technology meeting.GlobeNewswireCSSi LifeSciences Announces Rebrand to QNova LifeSciencesCSSi LifeSciences announced its rebrand to QNova LifeSciences, a global regulatory consulting firm for drug and medical device companies. The new name reflects its expanded services, including QNova Accelerator and QNova Capital, while the team and commitment remain unchanged.